Please Wait.....
Report
Cee, Russia & Cis Retinal Biologics Market Research Report Forecast to 2030
Market Report I 2023-07-06 I 97 Pages I Market Research Future
Cee, Russia & Cis Retinal Biologics Market Research Report Forecast to 2030
Market Overview
The growth of the CEE, Russia & CIS retinal biologics market is attributed to the rising R&D activities in retinal gene therapies, rising efforts for the development of retinal drugs, increasing adoption of retinal biologics for macular degeneration treatment, and increasing prevalence of chronic retinal diseases. However, regulatory obstructions, concerns pertaining to the adverse effects of biologic treatment, and initial high capital investment might hamper the market's growth in the forecast period.
Retinal biologics are drugs that are derived from living organisms or may contain derivatives from living organisms to treat a wide range of retinal disorders. Human eyes are highly delicate and can be affected by the minutest of things. Therefore, its security is of high importance. People across the globe are facing some serious retinal health disorders including diabetic retinopathy, infectious retinitis, age-related macular degeneration, macular edema, retinoblastoma, uveitis, retinal degeneration, retinoschisis, and macular hole.
However, the market is being held back by a lack of retinal biologics, dangerous biologic side effects, and limited access to retinal biologics and efficient treatments due to higher costs. Moreover, the market is being challenged by retinal biologics' side effects, which include retinal tears, sickness, and eye pain. The strict regulatory compliances associated with biologics approval imposed by governing authorities are impeding industry growth.
The growing geriatric population and associated diseases such as age-related macular degeneration (AMD) will be a driving factor in this market's growth. Furthermore, increased smoking and alcohol consumption creates several health issues, including diseases such as hypertension and hypercholesterolemia, which damages retinal vessels eventually will benefit the retinal biologics industry. For instance, according to Eurostat Statistics in 2019, Bulgaria recorded 28.7% consumes tobacco in the form of smoking on a daily basis. Moreover, according to the State Agency for the Prevention of Alcohol-Related Problems (PARPA), alcohol consumption increased by 0.23 liter per capita 2019 from 2018.
Market Segmentation
CEE, Russia & CIS retinal biologics market is classified into drug type, distribution channel, indication, and region.
Major Players
The key market players are F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Bayer AG, and
Amgen Inc.
?
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 11
1.1 OVERVIEW 11
2 MARKET INTRODUCTION 12
2.1 DEFINITION 12
2.2 SCOPE OF THE STUDY 12
2.3 RESEARCH OBJECTIVE 12
2.4 MARKET STRUCTURE 13
2.5 ASSUMPTIONS & LIMITATIONS 13
3 RESEARCH METHODOLOGY 14
3.1 DATA MINING 14
3.2 SECONDARY RESEARCH 15
3.3 PRIMARY RESEARCH 16
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 17
3.5 FORECASTING TECHNIQUES 18
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 19
3.6.1 BOTTOM-UP APPROACH 19
3.6.2 TOP-DOWN APPROACH 20
3.7 DATA TRIANGULATION 20
3.8 VALIDATION 21
4 MARKET DYNAMICS 22
4.1.1 ANALYSTS' COMMENTS 23
5 MARKET FACTOR ANALYSIS 25
5.1 VALUE CHAIN ANALYSIS 25
5.1.1 R&D 26
5.1.2 MANUFACTURING 26
5.1.3 DISTRIBUTION & SALES 26
5.1.4 POST-SALES MONITORING 26
5.2 PORTER'S FIVE FORCES MODEL 27
5.2.1 THREAT OF NEW ENTRANTS 27
5.2.2 BARGAINING POWER OF SUPPLIERS 27
5.2.3 THREAT OF SUBSTITUTES 28
5.2.4 BARGAINING POWER OF BUYERS 28
5.2.5 INTENSITY OF RIVALRY 28
5.3 IMPACT OF COVID-19 ON THE CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET 28
5.3.1 IMPACT ON SUPPLY CHAIN 28
5.3.2 IMPACT ON PRODUCTION 29
5.3.3 IMPACT ON MARKET PLAYERS 29
6 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS 30
6.1 OVERVIEW 30
6.2 TNF-? INHIBITOR 31
6.3 VEGF-A ANTAGONIST 32
7 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION 33
7.1 OVERVIEW 33
7.2 MACULAR DEGENERATION 35
7.3 DIABETIC RETINOPATHY 35
7.4 RETINITIS PIGMENTOSA DISEASE 36
7.5 UVEITIS 36
7.6 OTHERS 36
8 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL 37
8.1 OVERVIEW 37
8.2 HOSPITALS AND CLINICS 39
8.3 PHARMACIES 39
8.4 OTHERS 39
9 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY REGION 41
9.1 CEE COUNTRIES 43
9.1.1 POLAND 45
9.1.2 CZECH REPUBLIC 46
9.1.3 BULGARIA 47
9.1.4 HUNGARY 49
9.1.5 ROMANIA 50
9.1.6 REST OF CEE COUNTRIES 52
9.2 RUSSIA 53
9.3 CIS COUNTRIES 55
9.3.1 KAZAKHSTAN 57
9.3.2 BELARUS 58
9.3.3 ARMENIA 59
9.3.4 UZBEKISTAN 60
9.3.5 UKRAINE 61
9.3.6 REST OF CIS COUNTRIES 62
10 COMPETITIVE LANDSCAPE 64
10.1 OVERVIEW 64
10.2 COMPETITIVE BENCHMARKING 65
10.3 KEY DEVELOPMENTS & GROWTH STRATEGIES 66
10.3.1 PRODUCT LAUNCHES/PRODUCT APPROVALS 66
10.4 FINANCIAL MATRIX 66
10.4.1 SALES (USD MILLION), 2021 66
10.4.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021 67
11 COMPANY PROFILES 68
11.1 AMGEN INC. 68
11.1.1 COMPANY OVERVIEW 68
11.1.2 FINANCIAL OVERVIEW 69
11.1.3 PRODUCTS OFFERED 69
11.1.4 KEY DEVELOPMENTS 69
11.1.5 SWOT ANALYSIS 70
11.1.6 KEY STRATEGIES 70
11.2 NOVARTIS AG 71
11.2.1 COMPANY OVERVIEWS 71
11.2.2 FINANCIAL OVERVIEW 72
11.2.3 PRODUCTS OFFERED 73
11.2.4 KEY DEVELOPMENTS 73
11.2.5 SWOT ANALYSIS 73
11.2.6 KEY STRATEGIES 74
11.3 SAMSUNG BIOEPIS CO., LTD 75
11.3.1 COMPANY OVERVIEWS 75
11.3.2 FINANCIAL OVERVIEW 76
11.3.3 PRODUCTS OFFERED 76
11.3.4 KEY DEVELOPMENTS 77
11.3.5 KEY STRATEGIES 77
11.4 INTAS PHARMACEUTICALS LTD. 78
11.4.1 COMPANY OVERVIEW 78
11.4.2 FINANCIAL OVERVIEW 78
11.4.3 PRODUCTS OFFERED 78
11.4.4 KEY DEVELOPMENTS 78
11.4.5 SWOT ANALYSIS 79
11.4.6 KEY STRATEGIES 79
11.5 ABBVIE INC. 80
11.5.1 COMPANY OVERVIEW 80
11.5.2 FINANCIAL OVERVIEW 81
11.5.3 PRODUCTS OFFERED 81
11.5.4 KEY DEVELOPMENTS 82
11.5.5 KEY STRATEGIES 82
11.6 ALIMERA SCIENCES 83
11.6.1 COMPANY OVERVIEW 83
11.6.2 FINANCIAL OVERVIEW 83
11.6.3 PRODUCTS OFFERED 84
11.6.4 KEY DEVELOPMENTS 84
11.6.5 KEY STRATEGIES 84
11.7 BAYER AG 85
11.7.1 COMPANY OVERVIEWS 85
11.7.2 FINANCIAL OVERVIEW 86
11.7.3 PRODUCTS OFFERED 86
11.7.4 KEY DEVELOPMENTS 87
11.7.5 SWOT ANALYSIS 87
11.7.6 KEY STRATEGIES 87
11.8 POLPHARMA BIOLOGICS GROUP 88
11.8.1 COMPANY OVERVIEW 88
11.8.2 FINANCIAL OVERVIEW 88
11.8.3 PRODUCTS OFFERED 88
11.8.4 KEY DEVELOPMENTS 88
11.8.5 KEY STRATEGIES 88
11.9 SUN PHARMACEUTICAL INDUSTRIES LTD. 89
11.9.1 COMPANY OVERVIEW 89
11.9.2 FINANCIAL OVERVIEW 90
11.9.3 PRODUCTS OFFERED 90
11.9.4 KEY DEVELOPMENTS 91
11.9.5 KEY STRATEGIES 91
11.10 F. HOFFMANN-LA ROCHE LTD 92
11.10.1 COMPANY OVERVIEW 92
11.10.2 FINANCIAL OVERVIEW 93
11.10.3 PRODUCTS OFFERED 93
11.10.4 KEY DEVELOPMENTS 93
11.10.5 SWOT ANALYSIS 94
11.10.6 KEY STRATEGIES 94
12 APPENDIX 95
12.1 REFERENCES 95
12.2 RELATED REPORTS 96
?
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 13
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 16
TABLE 3 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 31
TABLE 4 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR TNF-? INHIBITOR, BY REGION, 2018-2030 (USD MILLION) 31
TABLE 5 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR VEGF-A ANTAGONIST, BY REGION, 2018-2030 (USD MILLION) 32
TABLE 6 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 34
TABLE 7 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION) 35
TABLE 8 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION) 35
TABLE 9 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR RETINITIS PIGMENTOSA DISEASE, BY REGION, 2018-2030 (USD MILLION) 36
TABLE 10 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR UVEITIS, BY REGION, 2018-2030 (USD MILLION) 36
TABLE 11 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION) 36
TABLE 12 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 38
TABLE 13 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION) 39
TABLE 14 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR PHARMACIES, BY REGION, 2018-2030 (USD MILLION) 39
TABLE 15 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION) 39
TABLE 16 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY REGION, 2018-2030 (USD MILLION) 42
TABLE 17 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 42
TABLE 18 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 42
TABLE 19 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 43
TABLE 20 CEE: RETINAL BIOLOGICS MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 44
TABLE 21 CEE: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 44
TABLE 22 CEE: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 45
TABLE 23 CEE: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 45
TABLE 24 POLAND: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION) 45
TABLE 25 POLAND: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 46
TABLE 26 POLAND: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 46
TABLE 27 CZECH REPUBLIC: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 46
TABLE 28 CZECH REPUBLIC: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 47
TABLE 29 CZECH REPUBLIC: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 47
TABLE 30 BULGARIA: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS 2018-2030 (USD MILLION) 47
TABLE 31 BULGARIA: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 49
TABLE 32 BULGARIA CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 49
TABLE 33 HUNGARY: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 49
TABLE 34 HUNGARY: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY AGE GROUP, 2018-2030 (USD MILLION) 50
TABLE 35 UK: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 50
TABLE 36 ROMANIA: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 50
TABLE 37 ROMANIA: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 51
TABLE 38 ROMANIA: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 51
TABLE 39 REST OF CEE COUNTRIES: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 52
TABLE 40 REST OF CEE COUNTRIES: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 52
TABLE 41 REST OF CEE COUNTRIES: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 52
TABLE 42 RUSSIA: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 53
TABLE 43 RUSSIA: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 54
TABLE 44 RUSSIA: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 54
TABLE 45 CIS COUNTRIES: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 55
TABLE 46 CIS COUNTRIES: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 57
TABLE 47 CIS COUNTRIES: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 57
TABLE 48 KAZAKHSTAN: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 57
TABLE 49 KAZAKHSTAN: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 58
TABLE 50 KAZAKHSTAN: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 58
TABLE 51 BELARUS: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 58
TABLE 52 BELARUS: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 59
TABLE 53 BELARUS: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 59
TABLE 54 ARMENIA: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 59
TABLE 55 ARMENIA: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 60
TABLE 56 ARMENIA: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 60
TABLE 57 UZBEKISTAN: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 60
TABLE 58 UZBEKISTAN: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 61
TABLE 59 UZBEKISTAN: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 61
TABLE 60 UKRAINE: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 61
TABLE 61 UKRAINE: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 62
TABLE 62 UKRAINE: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 62
TABLE 63 REST OF CIS COUNTRIES: RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2018-2030 (USD MILLION) 62
TABLE 64 REST OF CIS COUNTRIES: RETINAL BIOLOGICS MARKET, BY INDICATION, 2018-2030 (USD MILLION) 63
TABLE 65 REST OF CIS COUNTRIES: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION) 63
TABLE 66 MAJOR PLAYERS IN THE CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET 64
TABLE 67 PRODUCT LAUNCHES/PRODUCT APPROVALS 66
TABLE 68 AMGEN INC.: PRODUCTS OFFERED 69
TABLE 69 NOVARTIS AG: PRODUCTS OFFERED 73
TABLE 70 NOVARTIS AG: KEY DEVELOPMENTS 73
TABLE 71 SAMSUNG BIOEPIS CO., LTD.: PRODUCTS OFFERED 76
TABLE 72 SAMSUNG BIOEPIS CO., LTD: KEY DEVELOPMENTS 77
TABLE 73 INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED 78
TABLE 74 ABBVIE INC.: PRODUCTS OFFERED 81
TABLE 75 ALIMERA SCIENCES: PRODUCTS OFFERED 84
TABLE 76 BAYER AG: PRODUCTS OFFERED 86
TABLE 77 POLPHARMA BIOLOGICS GROUP: PRODUCTS OFFERED 88
TABLE 78 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 90
TABLE 79 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 93
?
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 11
FIGURE 2 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET 13
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 19
FIGURE 4 DRIVERS: IMPACT ANALYSIS 23
FIGURE 5 RESTRAINT: IMPACT ANALYSIS 24
FIGURE 6 VALUE CHAIN ANALYSIS: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET 25
FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET 27
FIGURE 8 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET; DRUG CLASS SEGMENT ATTRACTIVENESS, (USD MILLION) 30
FIGURE 9 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2021 & 2030 (USD MILLION) 30
FIGURE 10 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET SHARE (%), BY DRUG CLASS, 2021 31
FIGURE 11 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET; INDICATION SEGMENT ATTRACTIVENESS, (USD MILLION) 33
FIGURE 12 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION, 2021 & 2030 (USD MILLION) 34
FIGURE 13 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET SHARE (%), BY INDICATION, 2021 35
FIGURE 14 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET; DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, (USD MILLION) 37
FIGURE 15 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2021 & 2030 (USD MILLION) 38
FIGURE 16 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2021 38
FIGURE 17 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY REGION, 2021 & 2030 (USD MILLION) 41
FIGURE 18 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET SHARE (%), BY REGION 2021 41
FIGURE 19 CEE RETINAL BIOLOGICS MARKET, 2021-2030 (USD MILLION) 43
FIGURE 20 CEE: RETINAL BIOLOGICS MARKET SHARE (%), BY REGION 2021 44
FIGURE 21 RUSSIA MARKET ANALYSIS, RETINAL BIOLOGICS MARKET, 2021-2030 (USD MILLION) 53
FIGURE 22 CIS COUNTRIES MARKET ANALYSIS, RETINAL BIOLOGICS MARKET, 2021-2030 (USD MILLION) 55
FIGURE 23 CIS COUNTRIES: RETINAL BIOLOGICS MARKET SHARE, BY COUNTRY 2021 (%) 55
FIGURE 24 BENCHMARKING OF MAJOR COMPETITORS 65
FIGURE 25 SALES, 2021 66
FIGURE 26 RESEARCH & DEVELOPMENT EXPENDITURE, 2021 67
FIGURE 27 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 69
FIGURE 28 AMGEN INC.: SWOT ANALYSIS 70
FIGURE 29 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 72
FIGURE 30 NOVARTIS AG: SWOT ANALYSIS 73
FIGURE 31 SAMSUNG BIOEPIS CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT 76
FIGURE 32 INTAS PHARMACEUTICALS LTD.: SWOT ANALYSIS 79
FIGURE 33 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT 81
FIGURE 34 ALIMERA SCIENCES: FINANCIAL OVERVIEW SNAPSHOT 83
FIGURE 35 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 86
FIGURE 36 BAYER AG: SWOT ANALYSIS 87
FIGURE 37 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 90
FIGURE 38 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 93
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 94
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security